The preparation is indicated for the management of Lower Urinary Tract Symptoms (LUTS) in men with Benign Prostatic Hyperplasia (BPH). Prostamol Uno is primarily used in situations involving certain distressing symptoms of LUTS associated with mild-to-moderate non-malignant enlargement of the prostate.

This phytotherapeutic agent is applied in addressing symptom clusters related to physical discomfort, commonly used when short-term symptomatic assistance is needed. The medicine is considered relevant for managing conditions presenting with symptoms of BPH, including voiding disturbances (like a weak stream), storage symptoms, and nocturia. It is often used during phases when symptoms become more noticeable, and may be part of symptomatic management for adult men managing chronic prostate changes.

By easing symptoms like a weak stream and urinary urgency, it contributes to improved comfort during periods of heightened symptoms.

Quick Fact: Relief for Nocturia The medication may assist with maintaining functional stability and is relevant for easing the frequency of nighttime urination.

Regulatory References

1. European Medicines Agency's HMPC conclusions on Saw Palmetto Fruit

Who Can and Cannot Use Prostamol Uno?

The eligibility for using Prostamol Uno (Serenoa Repens Fructuum Extract) is strictly defined by regulatory documents, confining its use to a specific adult population and listing explicit contraindications.

Eligibility and Exclusions

Age and Conditional Restrictions

• Children and Adolescents (Under 18): Use is not recommended. Safety and efficacy data for this age group have not been established.
• Women: The product is not applicable and not intended for use in women, including those who are pregnant or breastfeeding, as the indication is limited to adult men.
• Hepatic/Renal Impairment: The safety of the product has not been established in patients with liver or kidney impairment due to a lack of data.

The official label mandates immediate medical consultation if symptoms such as blood in the urine, an overfilled bladder, or acute urinary retention occur, as the medicine is intended only for symptomatic relief.

The regulatory documentation for Serenoa Repens Fructuum Extract (the active component of Prostamol Uno) provides a narrow interaction profile, specifically defining potential constraints regarding anticoagulant therapy. This profile is defined by official statements that define co-administration rules rather than detailing underlying metabolic pathways.

Interaction Scope

Regulatory Classification and Official Statements

The potential interaction with warfarin is categorized by regulatory authorities as a suspected pharmacodynamic interaction, based on reports of observed effects.

Official Interaction Statements:

• A suspected interaction has been officially reported with the oral anticoagulant warfarin.
• Co-administration has been linked to an observed increase in International Normalized Ratio (INR) values, which indicates an alteration in the measurable effect of the anticoagulant.
• No mandatory separation requirements or timing-based administration rules are documented in the official regulatory texts.
• No specific interactions with food, alcohol, or other herbal products are formally listed in the regulatory interaction sections.

The overall profile is defined by the absence of formally documented metabolic or transporter-mediated interactions, with the primary constraint focused on caution during concurrent use with anticoagulants to monitor for altered INR values.

The mechanism of action involves a multi-target approach that simultaneously influences three core pathways within the prostatic and surrounding urinary structures.

Targeting Hormonal Pathways to Constrain Prostatic Cell Proliferation

This domain focuses on the non-competitive inhibition of the 5-alpha-reductase enzyme (types I and II) within prostatic cells, which facilitates the conversion of testosterone into Dihydrotestosterone (DHT). By suppressing this conversion, the extract modulates androgenic signaling, leading to a constrained rate of prostatic tissue proliferation and a subsequent effect on tissue volume (static component modulation).

Dual Modulation of Inflammatory Signaling and Muscle Tone

The second domain engages two distinct functional pathways: the inflammatory cascade and the smooth muscle mechanism. The extract acts as a dual inhibitor of Cyclooxygenase and 5-Lipoxygenase, resulting in reduced production of inflammatory mediators. Concurrently, it acts as an antagonist at alpha1-adrenoceptors to modulate the resting tension of prostatic and bladder neck smooth muscle. This dual action modulates the functional and irritative signaling pathways by reducing fluid accumulation and muscle-induced tension (dynamic component modulation).

Prostamol Uno is utilized according to a standardized regimen that relies entirely on the oral route of administration. The therapeutic approach is defined by the 320 mg soft gelatin capsule, which constitutes the single dose of the extract. The standard schedule requires the capsule to be taken once daily. To ensure consistency and proper use, the dose must be administered after a meal at the same time every day. The integrity of the dosage form is crucial: the capsule must be swallowed whole with an adequate amount of liquid and is not intended to be opened or chewed. This approach is structured for long-term, sustained management, with continuous, regular use emphasized as a primary procedural condition. While the overall duration is dependent on the symptomatic course, noticeable effects are often referenced as appearing after approximately four weeks of use. Use is restricted to adult men and the elderly. Administration is not recommended for adolescents or children under 18 years. Procedural rules for managing omissions are explicit: if a dose is forgotten, the patient must not take a double dose to make up for the missed timing.

Research Evidence / Overview of Studies for Prostamol Uno

Evidence for use in Lower Urinary Tract Symptoms (LUTS)

The research base for the Serenoa repens extract used in this medicine includes a large number of clinical trials and comprehensive reviews that have been studied for its role in men experiencing Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH). The research examined its relevance in individuals experiencing conditions characterized by fluctuating or episodic manifestations of LUTS. Specifically, the evidence base includes many controlled studies designed to evaluate outcomes related to physical discomfort and changes in urinary function over defined time intervals.

Research has shown that the primary study design used is the Randomized Controlled Trial (RCT). In these trials, researchers explored various outcomes related to LUTS, focusing on how symptoms evolved in the observed populations. These outcomes include patient-reported outcomes describing perceived discomfort and scores from standardized urologic symptom scales (like the IPSS). Findings were mixed across the body of research. Some studies reported patterns related to short-term changes in these metrics, while other large-scale, high-quality trials reported observations that were not statistically different from those seen with an inactive substance (placebo).

Studies on Specific Symptom Endpoints

Research has examined specific functional outcomes relevant in evidence describing how symptoms are measured. This includes research examining the frequency of nighttime urination (nocturia) and the severity of voiding issues, such as a weak stream. Furthermore, researchers applied in studies examining patient-reported experiences of how these symptoms affect daily life by using Quality of Life (QoL) measures. While research describes the evolution of symptoms in terms of these specific measures, the collective evidence is limited in providing a clear, uniform picture of the findings across all trials.

Study Design and Comparisons

The study design used in the available research base includes both placebo-controlled trials and comparative studies. Placebo-controlled trials are those where the extract was studied for how it measured against an identical-looking capsule containing no active ingredient. Comparative studies, on the other hand, research examined how the extract’s measured outcomes compared to those of established pharmaceutical treatments used in research exploring how symptoms change over time for LUTS/BPH. These comparisons were evaluated in trials that included other active pharmaceutical treatments as controls.

What is Still Uncertain About the Evidence

The primary gap in the research landscape is the inconsistency of findings reported in different high-quality clinical trials, particularly concerning the measurement against placebo. This makes it challenging to generalize findings across all populations. Another key factor is the variability in extract type. Because different research studies evaluated different preparations of Serenoa repens (e.g., ethanolic vs. hexane extracts), this was observed in some studies to be a factor that complicates the generalization of findings to all commercial products. Overall, the evidence quality varies across studies, and the findings describe group patterns, not personal outcomes; research does not determine whether an individual will respond similarly.

Common questions about Prostamol Uno (FAQ)

Q: Is it normal to feel a change in frequency after a few days of taking Prostamol Uno?

The official documents related to the use of the product state that noticeable effects on symptoms are typically referenced as appearing after approximately four weeks of continuous use. Any specific changes in urinary frequency within the first few days of starting treatment are not typically documented in this timeframe.

Q: What is the difference between Prostamol Uno and other saw palmetto products?

According to official regulatory guidance, this product is classified as a registered herbal medicinal product. This means it uses a standardized, concentrated extract, which is important because it ensures a defined and consistent amount of the active substance. This level of standardization distinguishes it from many non-standardized dietary supplements containing saw palmetto.

Q: Can Prostamol Uno be taken by people with stomach sensitivity?

Gastrointestinal side effects, such as nausea or abdominal pain, are listed as uncommon side effects. Regulatory documents state that these effects are reported to occur more frequently when the capsule is taken on an empty stomach. The product is generally instructed to be taken after a meal, a procedural step that is referenced as helping to reduce the incidence of these digestive effects.

Q: Can I stop taking Prostamol Uno abruptly?

The prescribed regimen for this product is structured for long-term, sustained management of symptoms associated with BPH. The overall duration of the treatment is dependent on the symptomatic course of the condition. Guidance on stopping the medication regimen is subject to individual circumstances.

Q: What is the active component of the Serenoa repens extract in Prostamol Uno?

The active substance in the medicine is the Serenoa Repens Fructuum Extract. However, its pharmacological activity is attributed not to a single molecule, but to a complex mixture of lipophilic components, which mainly include free fatty acids and phytosterols.

Q: What should be done if an adverse event is suspected while taking Prostamol Uno?

Official guidance indicates that patients and healthcare professionals should report any suspected side effects to the national competent authorities responsible for drug monitoring. The necessary information and procedures for reporting a suspected adverse event are typically detailed in the medicine's package leaflet.

Q: Does Prostamol Uno affect kidney function tests?

Regulatory documents indicate that the safety of this product has not been established in patients with liver or kidney impairment due to a lack of relevant data. Official information does not specify whether the medicine directly interferes with or alters the results of routine kidney function laboratory tests.

Q: How does the official literature describe the duration of action for Prostamol Uno?

The official literature describes the product in the context of long-term, sustained symptom management. Efficacy is evaluated over continuous treatment intervals, such as several months or years. The documents focus on symptom progression over this long-term usage rather than the half-life or duration of effect of a single dose once the regimen is established.

Q: Is Prostamol Uno used for hair loss in any official capacity?

The official and approved therapeutic indication for this product is limited to the relief of Lower Urinary Tract Symptoms (LUTS) associated with Benign Prostatic Hyperplasia (BPH) in adult men. No other official capacity or indication is documented in the regulatory texts.

Q: Does Prostamol Uno interact with common pain relievers like ibuprofen?

No specific interaction with ibuprofen or other common pain relievers is formally listed in the official interaction sections. Regulatory documents note a suspected interaction with the anticoagulant warfarin due to a potential increased bleeding risk, but no specific interaction with ibuprofen is formally listed.

Q: Can the effectiveness of Prostamol Uno decrease over time?

Research, including clinical trials and long-term observational studies, has examined the sustained effect of the extract over extended periods. Regulatory documents do not contain statements indicating that the effectiveness of the product decreases over time due to tolerance or tachyphylaxis.

Q: Does Prostamol Uno impact sexual function?

Sexual dysfunction is not formally listed as an adverse reaction in the official product information. Some clinical studies using the active extract have examined measures of sexual function and reported findings that indicated no significant negative impact on these parameters.

Q: What happens if a person who is not eligible mistakenly takes Prostamol Uno?

Regulatory documents specify that the product is contraindicated for women (including those who are pregnant or breastfeeding) and it is not recommended for children or adolescents. In the event of accidental ingestion by an individual who is not eligible for use, professional medical assessment is necessary to determine the appropriate next steps.

How to Store and Dispose of Prostamol Uno

The storage and disposal of Prostamol Uno must strictly adhere to the conditions documented in the official regulatory product information.

Storage Requirements

Disposal Instructions

Medicinal products must not be disposed of via wastewater or placed into household waste containers.

To ensure proper handling and environmental protection, users are required to ask a pharmacist for guidance on how to safely dispose of any unused or expired Prostamol Uno capsules.